Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum is attractive because its post-spin cleanup is creating a simpler, higher-quality medtech platform with global sales of $8.2B and a $93B+ addressable market, while management is actively divesting non-core assets, paying down debt, and improving execution. Growth is being driven by MedSurg’s underpenetrated infection prevention and wound care opportunities, Dental’s mix-led strength from new products, and a highly sticky HIS franchise with ~80% RCM share, even as the company maintains a 4%-5% organic growth outlook. The investment case is further strengthened by expected margin expansion from pricing, mix, and $500M of cumulative Transform for the Future savings, plus a free-cash-flow inflection expected in 4Q26 as separation costs roll off.

Solventum is vulnerable to slower growth in its largest businesses, with medsurg now about 64% of revenue and dental solutions and health information systems each around 18%, leaving the company heavily exposed to any weakness in a few key end markets. Even though FY26 guidance improved to 2.5% to 3.0% organic revenue growth and $7.10 to $7.20 of adjusted EPS, the outlook remains pressured by slower operating margin expansion, higher interest expense from rising rates, tariff and SKU-related distortions, and the risk that ERP advanced orders reverse primarily within 3Q26. The company also faces execution risk from the HIS separation, higher competition, TSA and standalone-company costs, and a valuation framework that already reflects a lower-growth profile than peers.